Tivic Health Systems, Inc. (TIVC)

TIVC's stock has experienced significant volatility and decline. The stock price decreased by 72.84% between December 31, 2024, and December 30, 2025, and 73.11% over the last 12 months. Key events include a 1-for-100 reverse stock split in August 2023, securing exclusive rights for Entolimod in February 2025, and expanding the licensing option for Entolimod to include neutropenia in March 2025. In Q3 2025, Tivic Health reported a net loss of $2.6 million on $146,000 in revenue. In December 2025, Tivic Health acquired manufacturing assets, launching Velocity Bioworks™, backed by a financing package. In January 2026, the company announced a 200-fold manufacturing scale-up for Entolimod.

Demand for Tivic Health Systems' products varies by product line. ClearUP Sinus Relief experiences seasonal demand fluctuations, particularly during spring allergy season. Demand for biopharmaceutical products like Entolimod is less driven by consumer seasonality, with ARS treatment demand being event-driven and neutropenia treatment demand tied to medical conditions.

Tivic Health Systems, Inc. is a health technology company that has transformed into a diversified therapeutics company with a biopharmaceutical pipeline. Initially focused on bioelectronic medicine, its primary product is ClearUP Sinus Relief, a handheld device for alleviating sinus pain and congestion. The company has shifted to immunotherapeutics, acquiring rights to Entolimod and Entolasta for treating conditions like acute radiation syndrome and neutropenia.

Tivic Health Systems, Inc. is headquartered in Fremont, California, United States. ClearUP is sold direct-to-consumer through its websites and major online retailers like Amazon.com and Walmart.com. While initially focused on the U.S. market, Tivic Health is evaluating international expansion opportunities.

Tivic Health Systems has focused on improving its commercial business and advancing its biopharmaceutical pipeline. The launch of ClearUP 2.0 improved customer experience, with reviews reaching 4.4 stars, positively impacting the brand reputation of its consumer product. However, financial challenges, including negative margins and declining revenue, could negatively impact its reputation among investors. The strategic pivot to immunotherapeutics presents transformation risks that can influence investor perception.

Tivic Health Systems has a diverse ownership structure. Institutional investors hold approximately 4.25% of the stock, insiders own 84.21%, and retail investors account for 4.67%. John Claude owns 67.73% of the company. Other significant individual insiders are Blake Gurfein and Briana Benz. Major institutional owners include Lasry Marc, DRW Securities, LLC, Marex Group plc, and others that have filed 13D/G or 13F forms with the SEC.